We still don't know how to stop Alzheimer's disease. After decades of research, billions of dollars, and enough failed drug trials to fill a very depressing library, the disease continues to outsmart us. But a team at Kyoto University just showed that waking up the brain's dormant stem cells doesn't just produce shiny new neurons - it actually helps clean up the amyloid-beta plaques that are Alzheimer's calling card. And the whole thing hinges on an energy-sensing pathway that nobody had on their bingo card.

Your Brain's Forgotten Factory

Here's something your brain would rather you didn't know: it mostly stopped making new neurons a while ago. The hippocampus - your brain's memory headquarters - has neural stem cells (NSCs) that are supposed to keep churning out fresh neurons throughout your life. In practice, they slowly go dormant with age, like employees who figured out how to look busy while doing absolutely nothing. In Alzheimer's disease, this shutdown happens even faster, and the consequences are brutal: fewer new neurons means worse memory, less cognitive flexibility, and a brain that's increasingly bad at taking out its own trash (Moreno-Jimenez et al., 2019).

The trash in question? Amyloid-beta (Aβ), those sticky protein fragments that clump together into plaques and are basically the hallmark of Alzheimer's pathology. The conventional approach has been to attack these plaques directly with antibodies (looking at you, lecanemab and donanemab). But what if you could get the brain to clean up after itself by simply turning the stem cell factory back on?

The iPaD: Not the One You're Thinking Of

The Kyoto team, led by Masahiro Fukui and Ryoichiro Kageyama, previously developed a two-pronged molecular trick called iPaD - which stands for inducing Plagl2 and antagonizing Dyrk1a. (Neuroscientists love their acronyms the way cats love knocking things off tables.) Plagl2 is a transcription factor that tells stem cells to wake up and get to work, while Dyrk1a is a kinase that essentially tells them to stay in bed. Overexpress one, knock down the other, and aged stem cells start behaving like they're young again, producing neurons at levels normally seen in juvenile brains (Kaise et al., 2022).

In their new study, published in Cell Reports, they applied this iPaD treatment specifically to neural stem cells in 5xFAD mice - a mouse model engineered to develop aggressive Alzheimer's-like pathology. The results were, frankly, remarkable (Fukui et al., 2026).

What Happened When They Flipped the Switch

The iPaD-treated mice showed three big wins. First, neurogenesis cranked back up - more new neurons in the hippocampus, as expected. Second, amyloid-beta deposits actually decreased. Third (and this is the part that matters most to actual patients, or at least to mice trying to navigate a water maze), cognitive function improved significantly.

But here's where the story gets genuinely interesting. When the researchers looked at gene expression across the hippocampus, they found widespread changes. Genes associated with astrocyte and microglial activation - the brain's cleanup crew - were upregulated. These are the cells responsible for phagocytosis, essentially eating amyloid-beta plaques for lunch. Meanwhile, several genes that are typically overexpressed in Alzheimer's disease got dialed back down.

Enter Prkag2: The Plot Twist

Among those downregulated genes, one stood out: Prkag2. This gene encodes the gamma-2 regulatory subunit of AMPK (AMP-activated protein kinase), the cell's master energy sensor. Previous research had already flagged PRKAG2 as suspicious - its expression is roughly three times higher in Alzheimer's brains, and its protein levels correlate positively with amyloid-beta accumulation (Bharadwaj & Martins, 2020).

When the team specifically knocked down Prkag2 in the hippocampus, it turned out to be the most effective single-gene intervention for both boosting neurogenesis and reducing amyloid-beta. The knockdown paradoxically increased expression of other AMPK subunits, activating AMPK signaling overall. Think of it like removing a faulty circuit breaker that was tripping the whole system - once Prkag2 was out of the way, the energy-sensing machinery actually worked better.

AMPK: The Janitor's Boss

Both iPaD treatment and Prkag2 knockdown converge on the same pathway: AMPK signaling. When AMPK gets properly activated, it switches on autophagy - the cell's internal recycling program that clears out damaged proteins and dysfunctional organelles. It also boosts mitochondrial function, improving the cell's energy production. In a disease characterized by protein accumulation and metabolic dysfunction, getting AMPK to do its job properly is like finally hiring a competent building manager for an apartment complex that's been falling apart for years.

The fact that two completely different interventions (rejuvenating stem cells vs. knocking down a single gene) both end up activating the same cleanup pathway suggests this isn't a fluke. AMPK signaling might be a genuine convergence point where neurogenesis and amyloid clearance meet, which is the kind of finding that makes drug developers sit up a little straighter.

What This Means (and What It Doesn't)

Let's be appropriately cautious here: these are mouse results. Mice that were engineered to get Alzheimer's, no less, which isn't exactly the same as the disease developing naturally in a human brain over decades. But the identification of Prkag2 as a potential therapeutic target is significant. It's druggable. It's specific. And it connects neurogenesis to amyloid clearance through a well-characterized metabolic pathway that we already know how to tinker with (metformin, anyone?).

The bigger picture is a shift in how we think about Alzheimer's treatment. Instead of just trying to remove plaques after they've formed, this research suggests we might be able to prevent their accumulation by keeping the brain's own maintenance systems running properly. Your brain already knows how to clean up after itself - it just needs someone to wake up the night shift.

References:

1. Fukui, M., Kaise, T., Masaki, T., Sakamoto, T., & Kageyama, R. (2026). Activation of neurogenesis improves amyloid-β pathology and cognitive function through AMP kinase signaling in Alzheimer's disease model mice. Cell Reports, 44(4), 117250. DOI: 10.1016/j.celrep.2026.117250 | PubMed

2. Kaise, T., Fukui, M., Sueda, R., Piao, W., Yamada, M., Kobayashi, T., Imayoshi, I., & Kageyama, R. (2022). Functional rejuvenation of aged neural stem cells by Plagl2 and anti-Dyrk1a activity. Genes & Development, 36(1-2), 38-52. DOI: 10.1101/gad.349000.121 | PMCID: PMC8763050

3. Bharadwaj, P., & Martins, R.N. (2020). PRKAG2 Gene Expression Is Elevated and its Protein Levels Are Associated with Increased Amyloid-β Accumulation in the Alzheimer's Disease Brain. Journal of Alzheimer's Disease, 74(2), 441-448. DOI: 10.3233/JAD-190948 | PMCID: PMC7175932

4. Moreno-Jimenez, E.P., Flor-Garcia, M., Terreros-Roncal, J., Rabano, A., Cafini, F., Pallas-Bazarra, N., Avila, J., & Llorens-Martin, M. (2019). Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer's disease. Nature Medicine, 25, 554-560. DOI: 10.1038/s41591-019-0375-9

5. Herzig, S., & Shaw, R.J. (2018). AMPK: guardian of metabolism and mitochondrial homeostasis. Nature Reviews Molecular Cell Biology, 19, 121-135. DOI: 10.1038/nrm.2017.95

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.